Clinical Trial Update: A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Tarlatamab in combination with AB248 for extensive-stage small cell lung cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• AB248
• Tarlatamab (AMG-757) (Tarlatamab)

Snippet

Sponsor: Amgen | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 1 | Status: RECRUITING